PMID- 21786034
OWN - NLM
STAT- MEDLINE
DCOM- 20111205
LR  - 20211020
IS  - 1689-1392 (Electronic)
IS  - 1425-8153 (Print)
IS  - 1425-8153 (Linking)
VI  - 16
IP  - 3
DP  - 2011 Sep
TI  - Protective effect of intermedin on myocardial cell in a rat model of severe acute 
      pancreatitis.
PG  - 462-76
LID - 10.2478/s11658-011-0020-1 [doi]
AB  - Severe acute pancreatitis (SAP) is a common disease with a poor prognosis. Heart 
      failure is one cause of SAP patient death. Intermedin (IMD) is a potent 
      endogenous cardio-protective substance. Administration of exogenous IMD showed 
      beneficial effects in cardiovascular diseases. The aim of this study was to 
      investigate the myocardial damage in SAP and to determine the therapeutic 
      potential of IMD for SAP. Using an SAP rat model, we examined endogenous IMD 
      expression following SAP induction, and determined the effect of IMD on 
      myocardial function, histological morphology, apoptosis-related gene expression, 
      and prognosis. Our results indicated that the cardiac function and histological 
      structure were significantly disrupted in SAP rats. Infusion of exogenous IMD 
      significantly preserved cardiac function and ameliorated myocardial damage. 
      Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) 
      revealed that myocardial apoptosis was extensively present in SAP rats, and IMD 
      infusion led to increased expression of the prosurvival factor Bcl-2, but 
      decreased pro-apoptotic factors Bax and caspase-3. In addition, IMD infusion also 
      reversed the change of IMD receptor systems in SAP rat heart tissue. Furthermore, 
      we found that IMD infusion greatly decreased mortality of SAP rats. In 
      conclusion, administration of SAP produced therapeutic effects in SAP through 
      modulating apoptotic and pro-survival gene expression, inhibiting myocardial 
      apoptosis, preserving cardiac function, and a useful therapeutic agent for SAP, 
      and provides us an insight for a clinical trial of IMD for treating human severe 
      acute pancreatitis.
FAU - Du, Xiaodong
AU  - Du X
AD  - Department of Emergency Medicine, Sichuan University, Chengdu, 610041, China.
FAU - Cao, Yu
AU  - Cao Y
FAU - Xue, Ping
AU  - Xue P
FAU - Lin, Ziqi
AU  - Lin Z
FAU - Zeng, Zhi
AU  - Zeng Z
FAU - Xia, Qing
AU  - Xia Q
LA  - eng
PT  - Journal Article
DEP - 20110718
PL  - England
TA  - Cell Mol Biol Lett
JT  - Cellular & molecular biology letters
JID - 9607427
RN  - 0 (Neuropeptides)
RN  - 0 (Protective Agents)
RN  - 0 (Receptor Activity-Modifying Proteins)
RN  - 0 (bcl-2-Associated X Protein)
RN  - EC 3.4.22.- (Caspase 3)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Caspase 3/metabolism
MH  - Disease Models, Animal
MH  - Gene Expression Regulation/drug effects
MH  - Heart Function Tests
MH  - Humans
MH  - Male
MH  - Myocardium/enzymology/*pathology
MH  - Neuropeptides/administration & dosage/blood/metabolism/*pharmacology
MH  - Pancreatitis/blood/*pathology/physiopathology
MH  - Protective Agents/administration & dosage/metabolism/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor Activity-Modifying Proteins/genetics/metabolism
MH  - Survival Analysis
MH  - bcl-2-Associated X Protein/genetics/metabolism
PMC - PMC6275909
EDAT- 2011/07/26 06:00
MHDA- 2011/12/13 00:00
PMCR- 2011/07/18
CRDT- 2011/07/26 06:00
PHST- 2011/04/10 00:00 [received]
PHST- 2011/07/11 00:00 [accepted]
PHST- 2011/07/26 06:00 [entrez]
PHST- 2011/07/26 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PHST- 2011/07/18 00:00 [pmc-release]
AID - 20 [pii]
AID - 10.2478/s11658-011-0020-1 [doi]
PST - ppublish
SO  - Cell Mol Biol Lett. 2011 Sep;16(3):462-76. doi: 10.2478/s11658-011-0020-1. Epub 
      2011 Jul 18.